SG155996A1 - Thermodynamically stable form of bay 43-9006 tosylate - Google Patents

Thermodynamically stable form of bay 43-9006 tosylate

Info

Publication number: SG155996A1
Authority: SG; Singapore
Prior art keywords: thermodynamically stable; tosylate; bay; stable form; amino
Prior art date: 2004-09-29

Application number

SG200906448-6A

Other languages

English (en)

Inventor

Alfons Grunenberg

Jana Lenz

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2005-09-20

Publication date

2009-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-20 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2009-10-29 Publication of SG155996A1 publication Critical patent/SG155996A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Paper (AREA)
Catalysts (AREA)
Glass Compositions (AREA)

SG200906448-6A 2004-09-29 2005-09-20 Thermodynamically stable form of bay 43-9006 tosylate SG155996A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04023130		2004-09-29

Publications (1)

Publication Number	Publication Date
SG155996A1 true SG155996A1 (en)	2009-10-29

Family

ID=35482258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200906448-6A SG155996A1 (en)	2004-09-29	2005-09-20	Thermodynamically stable form of bay 43-9006 tosylate

Country Status (32)

Country	Link
US (1)	US8877933B2 (pl)
EP (1)	EP1797038B1 (pl)
JP (2)	JP5215666B2 (pl)
KR (4)	KR101239489B1 (pl)
CN (1)	CN101065360B (pl)
AR (1)	AR051301A1 (pl)
AU (1)	AU2005289100B2 (pl)
BR (1)	BRPI0515946A (pl)
CA (1)	CA2581843C (pl)
CU (1)	CU20070068A7 (pl)
CY (1)	CY1113598T1 (pl)
DK (1)	DK1797038T3 (pl)
EC (1)	ECSP077356A (pl)
ES (1)	ES2387812T3 (pl)
GT (1)	GT200500270A (pl)
HN (1)	HN2005000722A (pl)
HR (1)	HRP20120662T1 (pl)
IL (1)	IL181734A (pl)
MA (1)	MA28880B1 (pl)
MY (1)	MY176929A (pl)
NO (1)	NO344272B1 (pl)
NZ (1)	NZ553804A (pl)
PE (3)	PE20100445A1 (pl)
PL (1)	PL1797038T3 (pl)
PT (1)	PT1797038E (pl)
SG (1)	SG155996A1 (pl)
SI (1)	SI1797038T1 (pl)
TW (1)	TWI382016B (pl)
UA (1)	UA91520C2 (pl)
UY (1)	UY29144A1 (pl)
WO (1)	WO2006034797A1 (pl)
ZA (1)	ZA200702510B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE556713T1 (de)	1999-01-13	2012-05-15	Bayer Healthcare Llc	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US10653684B2 (en)	2002-02-11	2020-05-19	Bayer Healthcare Llc	Aryl ureas with angiogenisis inhibiting activity
AU2003209116A1 (en)	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en)	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) *	2003-05-20	2008-03-27	Bayer Pharmaceuticals Corp	Diarilureias com actividade inibidora de cinase
NZ544920A (en)	2003-07-23	2009-11-27	Bayer Healthcare Llc	4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR101239489B1 (ko)	2004-09-29	2013-03-06	바이엘 파마 악티엔게젤샤프트	열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
NZ561178A (en)	2005-03-07	2010-11-26	Bayer Schering Pharma Ag	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CA2627875A1 (en) *	2005-10-31	2007-05-10	Bayer Pharmaceuticals Corporation	Combinations comprising sorafenib and interferon for the treatment of cancer
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100113533A1 (en) *	2006-11-14	2010-05-06	Bayer Schering Pharma Aktiengesellschaft	Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
CN101220024A (zh) *	2007-12-11	2008-07-16	杜晓敏	一组抑制激酶的抗癌化合物
EP2231612A1 (en)	2008-01-17	2010-09-29	Sicor, Inc.	Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2009106825A1 (en) *	2008-02-27	2009-09-03	Cipla Limited	Polymorphs of sorafenib and salts thereof
WO2010079498A2 (en) *	2009-01-12	2010-07-15	Hetero Research Foundation	Novel polymorph of sorafenib tosylate
CA2758136A1 (en) *	2009-04-15	2010-10-21	Fondazione Irccs Istituto Nazionale Dei Tumori	Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
WO2010142678A2 (en) *	2009-06-12	2010-12-16	Ratiopharm Gmbh	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
EP2480534A1 (en)	2009-09-24	2012-08-01	Ranbaxy Laboratories Limited	Process for the preparation of sorafenib tosylate
EP2480535A1 (en)	2009-09-24	2012-08-01	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
US8552197B2 (en)	2009-11-12	2013-10-08	Ranbaxy Laboratories Limited	Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
US8618305B2 (en)	2010-01-29	2013-12-31	Ranbaxy Laboratories Limited	Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AP2013006834A0 (en)	2010-10-01	2013-04-30	Bayer Ip Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Solid state forms of sorafenib besylate, and processes for preparations thereof
CA2840491A1 (en)	2011-06-28	2013-01-03	Bayer Healthcare Llc	Topical ophthalmological pharmaceutical composition containing sorafenib
EP2559431A1 (en)	2011-08-17	2013-02-20	Ratiopharm GmbH	Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
US9227938B2 (en)	2012-01-23	2016-01-05	Sandoz Ag	Pharmaceutical composition containing crystalline sorafenib tosylate
EP2852574B1 (en) *	2012-05-21	2020-02-05	Hetero Research Foundation	Process for sorafenib tosylate polymorph iii
WO2013175483A1 (en) *	2012-05-23	2013-11-28	Shilpa Medicare Limited	Process for preparing crystalline sorafenib tosylate
CN103570613B (zh)	2012-07-18	2016-06-15	苏州泽璟生物制药有限公司	氘代ω-二苯基脲或其盐的多晶型物
CN103896833B (zh) *	2012-12-27	2016-12-28	上海创诺制药有限公司	索拉非尼对甲苯磺酸盐溶剂化物多晶型物及其制法和用途
WO2014118807A1 (en) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	A novel process for the preparation of sorafenib tosylate form iii
WO2014138905A1 (en) *	2013-03-14	2014-09-18	Apotex Technologies Inc.	Forms of sorafenib tosylate and processes for the preparation thereof
US9765723B2 (en)	2013-05-10	2017-09-19	Denso Corporation	Fuel injection control device and fuel injection system
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
US20170114323A1 (en) *	2014-06-19	2017-04-27	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) *	2014-12-01	2016-03-30	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
RU2568638C1 (ru) *	2015-02-26	2015-11-20	Индивидуальный предприниматель Михайлов Олег Ростиславович	КРИСТАЛЛИЧЕСКАЯ β-МОДИФИКАЦИЯ 4-[4-({ [4-ХЛОРО-3-(ТРИФТОРОМЕТИЛ) ФЕНИЛ]КАРБАМОИЛ} АМИНО)ФЕНОКСИ]-N-МЕТИЛ-ПИРИДИН-2-КАРБОКСАМИДА п-ТОЛУОЛСУЛЬФОНАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3109236B1 (en) *	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN106336377A (zh) *	2015-07-17	2017-01-18	苏州亚宝药物研发有限公司	一种甲苯磺酸索拉非尼晶型ⅱ的制备方法
CN105503715A (zh) *	2015-12-03	2016-04-20	神威药业集团有限公司	一种索拉非尼半甲苯磺酸盐多晶型及其制备方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107759517A (zh) *	2016-08-23	2018-03-06	广州白云山医药集团股份有限公司白云山制药总厂	一种甲苯磺酸索拉非尼晶型ⅰ的制备方法
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN108164459B (zh) *	2016-12-07	2021-07-27	上海创诺制药有限公司	甲苯磺酸索拉非尼晶型iii的制备方法
EP4374925A3 (en)	2017-01-05	2025-01-15	Radius Pharmaceuticals, Inc.	Polymorphic forms of rad1901-2hcl
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
US11179322B2 (en)	2018-07-10	2021-11-23	Novocure Gmbh	Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en)	2018-09-07	2018-11-22	Alvogen Malta Operations (Row) Ltd	Solid dosage form containing sorafenib tosylate
US20210401859A1 (en)	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CN110156671A (zh) *	2019-06-06	2019-08-23	杭州中美华东制药有限公司	新型的索拉非尼共晶及其制备方法
EP4007585A4 (en)	2019-08-02	2023-11-08	OneHealthCompany, Inc.	TREATMENT OF CANINE CANCERS
CN117088809A (zh) *	2022-05-12	2023-11-21	浙江工业大学	一种索拉非尼-丙二酸共晶及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5629425A (en) *	1994-09-19	1997-05-13	Eli Lilly And Company	Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410190A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
AU1153097A (en) *	1996-06-07	1998-01-05	Eisai Co. Ltd.	Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TR199900639T2 (xx)	1996-09-23	1999-06-21	Eli Lilly And Company	Olanzapin dihidrat D.
US6187799B1 (en) *	1997-05-23	2001-02-13	Onyx Pharmaceuticals	Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) *	1997-05-23	2002-02-05	Bayer Corporation	Inhibition of p38 kinase activity by aryl ureas
US7517880B2 (en) *	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) *	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7351834B1 (en) *	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) *	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) *	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE556713T1 (de)	1999-01-13	2012-05-15	Bayer Healthcare Llc	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
EP1140840B1 (en) *	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) *	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2002351196A1 (en) *	2001-12-03	2003-06-17	Bayer Pharmaceuticals Corporation	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
GB0129876D0 (en)	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1474393A1 (en) *	2002-02-11	2004-11-10	Bayer Pharmaceuticals Corporation	Aryl ureas as kinase inhibitors
AU2003209116A1 (en) *	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) *	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
GB0203412D0 (en)	2002-02-13	2002-04-03	Pharmagene Lab Ltd	5-HT 2B receptor antagonists
US6965550B2 (en)	2002-03-29	2005-11-15	Sony Corporation	Optical disk identifying device, optical disk identifying method, optical disk recorder, and optical disk reproducing device
EP1504047B1 (en) *	2002-05-03	2007-12-12	Janssen Pharmaceutica N.V.	Polymeric microemulsions
US7351534B2 (en) *	2003-01-27	2008-04-01	Oregon Health & Sciences University	Gene mutation associated with age-related macular degeneration
US7557129B2 (en) *	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7378233B2 (en) *	2003-04-12	2008-05-27	The Johns Hopkins University	BRAF mutation T1796A in thyroid cancers
PT1636585E (pt) *	2003-05-20	2008-03-27	Bayer Pharmaceuticals Corp	Diarilureias com actividade inibidora de cinase
NZ544920A (en) *	2003-07-23	2009-11-27	Bayer Healthcare Llc	4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2564325A1 (en) *	2004-04-30	2005-11-24	Bayer Pharmaceuticals Corporation	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
MY191349A (en) *	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1796642B1 (en) *	2004-08-27	2008-05-21	Bayer Pharmaceuticals Corporation	Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer
UA90691C2 (en) *	2004-09-29	2010-05-25	Баер Шеринг Фарма Акциенгезельшафт	Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
KR101239489B1 (ko)	2004-09-29	2013-03-06	바이엘 파마 악티엔게젤샤프트	열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
US7271763B2 (en) *	2005-03-03	2007-09-18	The United States Of America As Represented By The Secretary Of The Army	Hybrid-phased communication array
NZ561178A (en) *	2005-03-07	2010-11-26	Bayer Schering Pharma Ag	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2007053573A2 (en) *	2005-10-31	2007-05-10	Bayer Pharmaceuticals Corporation	Treatment of cancer with sorafenib
US8329408B2 (en) *	2005-10-31	2012-12-11	Bayer Healthcare Llc	Methods for prognosis and monitoring cancer therapy
AU2006312714A1 (en) *	2005-11-10	2007-05-18	Bayer Schering Pharma Aktiengesellschaft	Diaryl urea for treating pulmonary hypertension
CA2629863A1 (en) *	2005-11-14	2007-05-24	Scott Wilhelm	Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) *	2006-11-09	2010-03-11	Bayer Schering Pharma Aktiengesellschaft	Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US20100113533A1 (en) *	2006-11-14	2010-05-06	Bayer Schering Pharma Aktiengesellschaft	Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
CN101679362A (zh) *	2006-12-20	2010-03-24	拜尔保健公司	用于治疗癌症的 4 -{ 4 - [ ({ 3 -叔丁基 - 1 - [ 3 - (羟基甲基 )苯基 ] - 1 h -吡唑 - 5 -基} -氨基甲酰基)-氨基]-3-氟苯氧基}-n-甲基吡啶-2-甲酰氨及其前药和盐
CA2675979A1 (en) *	2007-01-19	2008-07-24	Bayer Healthcare Llc	Treatment of cancers having resistance to chemotherapeutic agents
JP5885012B2 (ja) *	2007-01-19	2016-03-15	バイエル・ヘルスケア・エルエルシーＢａｙｅｒＨｅａｌｔｈＣａｒｅＬＬＣ	Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
EP2231612A1 (en) *	2008-01-17	2010-09-29	Sicor, Inc.	Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2010048304A2 (en) *	2008-10-21	2010-04-29	Bayer Healthcare Llc	Identification of signature genes associated with hepatocellular carcinoma
AR081060A1 (es) *	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) *	2010-07-19	2013-08-01	バイエルヘルスケアリミティドライアビリティカンパニー	疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
AP2013006834A0 (en) *	2010-10-01	2013-04-30	Bayer Ip Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CA2840491A1 (en)	2011-06-28	2013-01-03	Bayer Healthcare Llc	Topical ophthalmological pharmaceutical composition containing sorafenib
WO2013000917A1 (en)	2011-06-28	2013-01-03	Bayer Intellectual Property Gmbh	Topical ophthalmological pharmaceutical composition containing regorafenib

2005
- 2005-09-20 KR KR1020107011544A patent/KR101239489B1/ko not_active Expired - Lifetime
- 2005-09-20 NZ NZ553804A patent/NZ553804A/en not_active IP Right Cessation
- 2005-09-20 SG SG200906448-6A patent/SG155996A1/en unknown
- 2005-09-20 UA UAA200704751A patent/UA91520C2/ru unknown
- 2005-09-20 JP JP2007533905A patent/JP5215666B2/ja not_active Expired - Lifetime
- 2005-09-20 US US11/664,363 patent/US8877933B2/en active Active
- 2005-09-20 PT PT05797740T patent/PT1797038E/pt unknown
- 2005-09-20 KR KR1020127030937A patent/KR101381454B1/ko not_active Expired - Lifetime
- 2005-09-20 ES ES05797740T patent/ES2387812T3/es not_active Expired - Lifetime
- 2005-09-20 KR KR1020077007003A patent/KR20070058537A/ko not_active Ceased
- 2005-09-20 WO PCT/EP2005/010119 patent/WO2006034797A1/en not_active Ceased
- 2005-09-20 CA CA2581843A patent/CA2581843C/en not_active Expired - Lifetime
- 2005-09-20 DK DK05797740.7T patent/DK1797038T3/da active
- 2005-09-20 PL PL05797740T patent/PL1797038T3/pl unknown
- 2005-09-20 SI SI200531571T patent/SI1797038T1/sl unknown
- 2005-09-20 HR HRP20120662TT patent/HRP20120662T1/hr unknown
- 2005-09-20 KR KR1020097001647A patent/KR20090018224A/ko not_active Ceased
- 2005-09-20 CN CN2005800407750A patent/CN101065360B/zh not_active Expired - Lifetime
- 2005-09-20 BR BRPI0515946-6A patent/BRPI0515946A/pt not_active Application Discontinuation
- 2005-09-20 EP EP05797740A patent/EP1797038B1/en not_active Revoked
- 2005-09-20 AU AU2005289100A patent/AU2005289100B2/en not_active Expired
- 2005-09-26 AR ARP050104016A patent/AR051301A1/es not_active Application Discontinuation
- 2005-09-27 MY MYPI20054554A patent/MY176929A/en unknown
- 2005-09-28 GT GT200500270A patent/GT200500270A/es unknown
- 2005-09-28 UY UY29144A patent/UY29144A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2009001132A patent/PE20100445A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2005001145A patent/PE20060699A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2014000731A patent/PE20142042A1/es active IP Right Grant
- 2005-09-28 TW TW094133622A patent/TWI382016B/zh not_active IP Right Cessation
- 2005-09-29 HN HN2005000722A patent/HN2005000722A/es unknown
2007
- 2007-03-06 IL IL181734A patent/IL181734A/en unknown
- 2007-03-22 NO NO20071508A patent/NO344272B1/no unknown
- 2007-03-26 CU CU20070068A patent/CU20070068A7/es unknown
- 2007-03-27 ZA ZA200702510A patent/ZA200702510B/xx unknown
- 2007-03-28 EC EC2007007356A patent/ECSP077356A/es unknown
- 2007-03-29 MA MA29784A patent/MA28880B1/fr unknown
2012
- 2012-08-24 CY CY20121100767T patent/CY1113598T1/el unknown
- 2012-12-20 JP JP2012278376A patent/JP2013100302A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MY176929A (en)	2020-08-27
NO344272B1 (no)	2019-10-21
EP1797038B1 (en)	2012-06-13
CA2581843A1 (en)	2006-04-06
ES2387812T3 (es)	2012-10-02
JP2008514658A (ja)	2008-05-08
NO20071508L (no)	2007-06-22
KR101239489B1 (ko)	2013-03-06
WO2006034797A1 (en)	2006-04-06
KR101381454B1 (ko)	2014-04-04
US8877933B2 (en)	2014-11-04
ZA200702510B (en)	2008-07-30
JP2013100302A (ja)	2013-05-23
CU20070068A7 (es)	2010-01-22
AU2005289100B2 (en)	2011-11-03
JP5215666B2 (ja)	2013-06-19
HK1114605A1 (en)	2008-11-07
US20090215833A1 (en)	2009-08-27
KR20130004385A (ko)	2013-01-09
IL181734A (en)	2015-10-29
HRP20120662T1 (hr)	2012-09-30
PE20100445A1 (es)	2010-07-04
PL1797038T3 (pl)	2012-11-30
KR20090018224A (ko)	2009-02-19
BRPI0515946A (pt)	2008-08-12
SI1797038T1 (sl)	2012-10-30
CY1113598T1 (el)	2016-06-22
NZ553804A (en)	2010-07-30
KR20070058537A (ko)	2007-06-08
PE20142042A1 (es)	2014-12-03
CN101065360A (zh)	2007-10-31
TW200626552A (en)	2006-08-01
AR051301A1 (es)	2007-01-03
AU2005289100A1 (en)	2006-04-06
HN2005000722A (es)	2010-08-19
CA2581843C (en)	2012-05-15
CN101065360B (zh)	2011-08-03
IL181734A0 (en)	2007-07-04
MA28880B1 (fr)	2007-09-03
PE20060699A1 (es)	2006-08-12
TWI382016B (zh)	2013-01-11
PT1797038E (pt)	2012-08-14
GT200500270A (es)	2006-04-25
KR20100061869A (ko)	2010-06-09
DK1797038T3 (da)	2012-09-03
UA91520C2 (en)	2010-08-10
ECSP077356A (es)	2007-04-26
EP1797038A1 (en)	2007-06-20
UY29144A1 (es)	2006-04-28

Publication	Publication Date	Title
SG155996A1 (en)	2009-10-29	Thermodynamically stable form of bay 43-9006 tosylate
TN2009000072A1 (en)	2010-08-19	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy}-n-methylpyridine-2-carboxamide monohydrate
IS8216A (is)	2005-12-30	4-(metýl súlfónýl amínó) fenýl hliðstæður sem vaníllóíð mótlyf, og sem sýna frábæra kvalastillandi virkni, og lyfjafræðilegar samsetningar, sem innihalda þær
TW200619220A (en)	2006-06-16	New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
TW200512206A (en)	2005-04-01	3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amion]-propionic acid ethylester-methanesulfonate and its use as a medicament
IL216803A0 (en)	2012-01-31	A binding protein capable of binding a p40 subunit of il-12 and il-23, a method for preparing the same and a pharmaceutical composition for reducing or inhibiting il-12 activity
WO2003062191A8 (en)	2004-01-15	N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
UA92349C2 (ru)	2010-10-25	Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
NZ604035A (en)	2015-02-27	Glycine transporter-1 inhibitors, methods of making them, and uses thereof
MX2021002261A (es)	2021-05-27	Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
TW200730507A (en)	2007-08-16	Pyrimidine derivatives for the treatment of abnormal cell growth
HUP0303027A2 (hu)	2003-12-29	Új benzoil-guanidin só és alkalmazása gyógyszerkészítmény előállítására
AU2005238141A8 (en)	2011-08-18	Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
WO2009005077A1 (ja)	2009-01-08	４－｛３－［４－（３－｛４－［アミノ（ブトキシカルボニルイミノ）メチル］フェノキシ｝プロピル）－１－ピペリジニル］プロポキシ｝－ｎ’－（ブトキシカルボニル）ベンズアミジンの新規な結晶
TH98396A (th)	2009-09-24	4-[4-({[4-คลอโร-3-(ไตรฟลูออโรเมทธิล)ฟีนิล]คาร์บาโมอิล}อะมิโน)-3-ฟลูออโรฟีนอกซี]-n-เมทธิลไพริดีน-2-คาร์บอกซาไมด์ โมโนไฮเดรท
TH87002B (th)	2022-03-15	กระบวนการเตรียมสารประกอบ 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}-N-methylpyridine-2-carboxamide
DK1708987T3 (da)	2011-06-27	L-(-)-moprolol-L-(+)-tartrat